ELATIVE
LIVE

Serial Number

79312182

Owner

GENFIT

Attorney

Brooks R. Bruneau

Filing Date

Jan 20, 2021

Add to watchlist:

No watchlists yet
View on USPTO

ELATIVE Trademark

Serial Number: 79312182 • Registration: 6681657

ELATIVE is a trademark filed by GENFIT on January 20, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

GENFIT (42 trademarks)

885 rue Eugene Avinee
Loos 59120 , FR

Entity Type: 03

Trademark Details

Filing Date

January 20, 2021

Registration Date

March 29, 2022

Published for Opposition

January 11, 2022

Goods & Services

Pharmaceutical preparations for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; chemical preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; organic preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; diagnostic preparations for medical use; diagnostic reagents for medical use

Scientific research for medical purposes; pharmaceutical research and development services; conducting clinical trials for pharmaceutical products for others, in particular conducting clinical trials for determining the efficacy and safety of elafibranor; conducting clinical trials for others to determine the efficacy and safety of pharmaceutical products in the treatment of primary biliary cholangitis (PBC); conducting scientific studies and analyses in the field of pharmaceuticals and medicines; scientific research and development, namely, providing information, results and data relating to scientific or medical research and development of pharmaceutical products, via an online searchable database; conducting clinical trials for others; pharmaceutical and biological product development and research services for third parties; conducting clinical research for others; evaluation of the efficacy of pharmaceutical products; clinical product development services

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jun 19, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 12, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 23, 2022 FICS
FINAL DISPOSITION PROCESSED
Aug 23, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 29, 2022 FICR
NEW REPRESENTATIVE AT IB RECEIVED
May 8, 2022 NREP
REGISTERED-PRINCIPAL REGISTER
Mar 29, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 11, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jan 11, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Jan 10, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 22, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 22, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 22, 2021 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 9, 2021 PREV
ASSIGNED TO LIE
Dec 9, 2021 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 8, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 6, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 6, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 6, 2021 TROA
REFUSAL PROCESSED BY IB
Sep 11, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 25, 2021 RFCS
REFUSAL PROCESSED BY MPU
Aug 25, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 7, 2021 RFCR
NON-FINAL ACTION WRITTEN
Aug 6, 2021 CNRT
ASSIGNED TO EXAMINER
Aug 3, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 12, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 8, 2021 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jun 7, 2021 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 3, 2021 REPR